Here’s why the PolyNovo (ASX:PNV) share price is jumping 13% today

PolyNovo has handed in its report card…

| More on:
A man takes his dividend and leaps for joy.

Image source: Getty Images

The PolyNovo Ltd (ASX: PNV) share price has been a strong performer on Tuesday.

At the time of writing, the medical device company’s shares are up 13% to $1.62.

Why is the PolyNovo share price jumping?

The rise in the PolyNovo share price today has been driven by the release of its second quarter and first half trading update this morning.

According to the release, during December, PolyNovo achieved record monthly US sales (ex Barda) of A$3.4 million (US$2.43 million). This was an increase of 76% over the prior corresponding period. Combined with strong sales results in October and November, this led to record second quarter US sales of US$2.43 million (US$5.86 million). This is an increase of 105% over the same period last year.

In light of the above, the company expects to report first half US sales of A$14.20 million (US$10.38 million). This will mean first half group sales growth of 45% year on year to A$16.28 million excluding Barda revenue and 43% including Barda revenue to A$18.04 million.

What drove its growth?

Underpinning this growth was the addition of a number of new customer accounts. During the first quarter, the company added 16 new accounts and then followed this up with 19 new accounts in the second quarter. This brought its total US accounts to 154.

Pleasingly, with the company intending to increase the size of the US sales team with a further 10 representatives, management expects to be able to expand its coverage across key cities and regions.

PolyNovo’s Senior VP Sales & Marketing Americas, Ed Graubart, said: “We have recruited top talent and they in turn are transitioning new accounts at a record pace. We have also filled some critical internal positions that allow for a more efficient and effective organisation. The team are buoyed by the strong results and opportunities.”

The company’s Chairman, David Williams, added: “While US sales are very encouraging, there is more to achieve as we still have new sales staff being onboarded and more staff to be employed. In addition, we are retraining existing staff to follow surgeon leads using the product in new indications. While the US is the engine room of our growth in the immediate future, there are many opportunities in the rest of the world where we are just starting out.”

Should you invest $1,000 in PolyNovo right now?

Before you consider PolyNovo, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and PolyNovo wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A smiling woman looks at her computer laptop in her home with warm lights in the background feeling happy to see the EMvision share price rising
Healthcare Shares

EMvision share price rockets 11% on $5 million pay day

Shares in the Australian medical device company shot higher today.

Read more »

retirement investing represented by older investor looking concerned at computer screen
Healthcare Shares

Why is the Medibank share price struggling to gain ground in May?

We check what's going on with shares in the private health insurer.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Healthcare Shares

Here’s why the Imugene share price just got a boost

Imugene's latest announcement is rallying up investors.

Read more »

A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
Healthcare Shares

Why the AnteoTech share price is rocketing 33% today

What did AnteoTech update the ASX with?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Growth Shares

Why CSL shares are ‘going to deliver’ in 2022: fund manager

Quality growth companies can perform well even in an era of rising interest rates.

Read more »

a group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Incannex share price pops 9% on FDA news

The medicinal cannabis drug development company came out with some positive developments from its FDA meeting...

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Broker Notes

Where next for the CSL share price?

CSL shares could be heading higher according to one leading broker...

Read more »

A telehealth doctor at her desk.
Healthcare Shares

Why is the Ramsay share price smashing the ASX 200 on Monday?

Ramsay shares are off to a positive start today.

Read more »